Last reviewed: May 12, 2026 Last updated: May 12, 2026 Written by: Jay Hastings , CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Produced in the gut after eating, GLP-1 stimulates insulin release, suppresses excess glucose production, and promotes feelings of fullness
Beyond the nervous system, GLP-1 signaling intersects with immune regulation
A Critical Analysis Please like and subscribe if you enjoyed this video Abstract The treatment landscape for managing weight in non-diabetic patients has changed dramatically with the introduction of glucagon-like peptide-1 (GLP-1) receptor agonists as anti-obesity drugs
We are able to bill many major insurers, including UMR, United, Optum, BlueCross BlueShield, Regence, Anthem, EMI, PEHP, SelectHealth, and DMBA
Studies show that people who stop semaglutide without maintaining lifestyle changes regain a substantial portion of lost weight within 12 months
